Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Overcoming antigen escape following CD19-directed CAR-T therapy

Pablo Domizi • 24 Apr 2022
The 2022 Tandem Meetings
General CAR-T

Pablo Domizi, PhD, Stanford University, Stanford, CA, comments on strategies to overcome antigen escape following CD19-directed therapy. Strategies targeting multiple antigens such as CD19, CD20, and CD22 may become more relevant in the future and it is likely that the CAR-T therapy field switches from single to multi-targeted CAR-T therapy. In addition, approaches to recover CD19 expression after relapse following CAR-T therapy are also a promising avenue to tackle antigen escape. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Pablo Domizi

3:01
Mechanisms of antigen escape following CD19-directed CAR-T therapy
Pablo Domizi • 24 Apr 2022
1:55
Using single-cell multiomics to predict patients at risk for antigen escape after CAR-T therapy
Pablo Domizi • 24 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals